Search in:

Advanced search

Expert Opinion on Therapeutic Patents Volume 18, 2008 - Issue 6

Submit an article Journal homepage

125

Views

CrossRef citations to date

Altmetric

Review

Recent advances in the discovery of non-peptidic direct renin inhibitors as antihypertensives: new patent applications in years 2000 – 2008

Fumiaki Yokokawa Novartis Pharma KK, Tsukuba Research Institute, Ohkubo 8 Tsukuba 300-2611, Japan +81 29 865 2137; +81 29 865 2308; [email protected]

Jürgen Maibaum Novartis Pharma AG, Novartis Campus, Forum 1, CH-4056 Basel, Switzerland

Pages 581-602 | Published online: 26 May 2008

Cite this article
https://doi.org/10.1517/13543776.18.6.581

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Chobanian AV, Bakins GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. J Am Med Assoc 2003;289:2560-72
PubMed Web of Science ®Google Scholar
Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
PubMed Web of Science ®Google Scholar
Amin Zaman M, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov 2002;1:621-36
PubMed Web of Science ®Google Scholar
Skeggs LT, Kahn JR, Lentz KE, et al. Preparation, purification and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957;106:439-53
PubMed Web of Science ®Google Scholar
Fisher NDL, Hollenberg NK. Renin inhibitors: what are the therapeutic opportunities? J Am Soc Nephrol 2005;16:592-9
PubMed Web of Science ®Google Scholar
Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006;24:243-56
PubMed Web of Science ®Google Scholar
Maibaum J, Feldman DL. Renin inhibitors as novel treatments for cardiovascular diseases. Expert Opin Ther Patents 2003;13:589-603
Web of Science ®Google Scholar
Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006;368:1449-56
PubMed Web of Science ®Google Scholar
Jensen CH, Herold P, Brunner HR. Aliskiren, the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008;7(5):399-410
PubMed Web of Science ®Google Scholar
Van Tassell BW, Munger MA. Aliskiren for renin inhibitors: a new class of antihypertensives. Ann Pharmacother 2007;41:456-64
PubMed Web of Science ®Google Scholar
Oh BH, Mitchell J, Herron J, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49:1157-63
PubMed Web of Science ®Google Scholar
Siragy HM, Kar S, Kirkpatrick P. Aliskiren Nat Rev Drug Discov 2007;6:779-80
Google Scholar
Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007;25:217-26
PubMed Web of Science ®Google Scholar
Drummond W, Munger MA, Essop MR, et al. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens 2007;9:742-50
PubMedGoogle Scholar
Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet 2007;370:221-9
PubMed Web of Science ®Google Scholar
Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008;26:589-99
PubMed Web of Science ®Google Scholar
James MN, Sielecki AR. Stereochemical analysis of peptide bond hydrolysis catalyzed by the aspartic proteinase penicillopepsin. Biochemistry 1985;24:3701-13
PubMed Web of Science ®Google Scholar
Raddatz P. Recent developments in renin inhibitors: part I. Expert Opin Ther Patents 1994;4:489-504
Google Scholar
Raddatz P. Recent developments in renin inhibitors: part II. Expert Opin Ther Patents 1994;4:1347-59
Google Scholar
Rasetti V, Cohen NC, Rüeger H, et al. Bioactive hydroxyethylene dipeptide isosteres with hydrophobic (P3-P1)-moieties. A novel strategy towards small non-peptide renin inhibitors. Bioorg Med Chem Lett 1996;6:1589-94
Google Scholar
Göschke R, Cohen NC, Wood JM, et al. Design and synthesis of novel 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides as in vitro potent peptidomimetic inhibitors of human renin. Bioorg Med Chem Lett 1997;7:2735-40
Google Scholar
Rahuel J, Rasetti V, Maibaum J, et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 2000;7:493-504
PubMed Web of Science ®Google Scholar
Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308:698-705
PubMed Web of Science ®Google Scholar
Göschke R, Stutz S, Rasetti V, et al. Novel 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamide transition state peptidomimetics are potent and orally active inhibitors of human renin. J Med Chem 2007;50:4818-31
PubMedGoogle Scholar
Maibaum J, Stutz S, Göschke R, et al. Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets. J Med Chem 2007;50:4832-44
PubMed Web of Science ®Google Scholar
Wood JM, Schnell CR, Cumin F, et al. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J. Hypertens 2005;23:417-26
PubMed Web of Science ®Google Scholar
Ganten D, Wagner J, Zen K, et al. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci 1992;89:7806-10
PubMed Web of Science ®Google Scholar
Rigel DF, Fu F, Li S, et al. The renin inhibitor aliskiren is a potent and long-acting antihypertensive in double transgenic rats expressing human renin and angiotensinogen genes. J Am Coll Cardiol 2004;43:483A
PubMed Web of Science ®Google Scholar
Pilz B, Shagdarsuren E, Wellner M, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46:569-76
PubMed Web of Science ®Google Scholar
Kelly DJ, Wilkinson-Berka JL, Allen TJ, et al. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int 1998;54:343-52
PubMed Web of Science ®Google Scholar
Pilz B, Shagdasurren E, Wellner M, et al. Aliskiren, a human renin inhibitor, reverses angiotensin II-induced renal and cardiac damage in dTGR in a regression study design [abstract]. Hypertension 2004;44:526-7
Google Scholar
Vieira E, Binggeli A, Breu V, et al. Substituted piperidines-highly potent renin inhibitors due to induced fit adaptation of the active site. Bioorg Med Chem Lett 1999;9:1397-402
PubMed Web of Science ®Google Scholar
Güller R, Binggeli A, Breu V, et al. Piperidine-renin inhibitors compounds with improved physicochemical properties. Bioorg Med Chem Lett 1999;9:1403-8
PubMed Web of Science ®Google Scholar
Oefner C, Binggeli A, Breu V, et al. Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases. Chem Biol 1999;6:127-31
PubMed Web of Science ®Google Scholar
Märki HP, Binggeli A, Bittner B, et al. Piperidine renin inhibitors: from lead to drug candidates. Il Farmaco 2001;56:21-7
PubMedGoogle Scholar
Bursavich MG, Rich DH. Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles. J Med Chem 2002;45:541-58
PubMed Web of Science ®Google Scholar
Bittner B, Chou R, Schleimer M, et al. Preformulation approaches to improve the oral bioavailability of two novel piperidine renin inhibitors in dog. Arzneimittelforschung 2002;52:593-9
PubMed Web of Science ®Google Scholar
Limongelli V, Marinelli L, Cosconati S, et al. Ensemble-docking approach on BACE-1: pharmacophore perception and guidelines for drug design. ChemMedChem 2007;2:667-78
PubMedGoogle Scholar
Tice CM. Renin inhibitors. In: Wood A, editor, Annual reports in Med Chem. Elsevier, Inc.; 2006;41:155-67
Google Scholar
Kasani A, Subedi R, Stier M, et al. Cardiovascular agents: renin inhibitors and factor Xa inhibitors. Heterocycles 2007;73:47-85
Google Scholar
Actelion Pharm. Ltd. WO03093267; 2003
Google Scholar
Actelion Pharm. Ltd. WO04096804; 2004
Google Scholar
Actelion Pharm. Ltd. WO04096116; 2004
Google Scholar
Actelion Pharm. Ltd. WO04096366; 2004
Google Scholar
Actelion Pharm. Ltd. WO04096799; 2004
Google Scholar
Actelion Pharm. Ltd. WO04096803; 2004
Google Scholar
Actelion Pharm. Ltd. WO05040173; 2005
Google Scholar
Actelion Pharm. Ltd. WO05040165; 2005
Google Scholar
Actelion Pharm. Ltd. WO05054243; 2005
Google Scholar
Actelion pharm. Ltd. WO05054244; 2005
Google Scholar
Actelion Pharm. Ltd. WO06021401; 2006
Google Scholar
Actelion Pharm. Ltd. WO06021402; 2006
Google Scholar
Actelion Pharm. Ltd. WO06021403; 2006
Google Scholar
Actelion Pharm. Ltd. WO06021399; 2006
Google Scholar
Actelion Pharm. Ltd. WO06058546; 2006
Google Scholar
Actelion Pharm. Ltd. WO06061791; 2006
Google Scholar
Actelion Pharm. Ltd. WO06063610; 2006
Google Scholar
Actelion Pharm. Ltd. WO06064484; 2006
Google Scholar
Actelion Pharm. Ltd. WO06079981; 2006
Google Scholar
Actelion Pharm. Ltd. WO06092268; 2006
Google Scholar
Actelion Pharm. Ltd. WO06131884; 2006
Google Scholar
Actelion Pharm. Ltd. WO04002957; 2004
Google Scholar
Actelion Pharm. Ltd. WO05040120; 2005
Google Scholar
Novartis AG. WO06074924; 2006
Google Scholar
Actelion Pharm. Ltd. WO07049224; 2007
Google Scholar
Novartis AG. WO05051911; 2005
Google Scholar
Novartis AG. WO06069788; 2006
Google Scholar
Novartis AG. WO06094763; 2006
Google Scholar
Novartis AG. WO06125621; 2006
Google Scholar
Actelion Pharm. Ltd. WO07088514; 2007
Google Scholar
Actelion Pharm. Ltd. WO06129237; 2006
Google Scholar
Actelion Pharm. Ltd. WO07102127; 2007
Google Scholar
Werner-Lambert Co. WO04089903; 2004
Google Scholar
CODY WL, Holsworth DD, Powell NA, et al. The discovery and preparation of disubstituted novel amino-aryl-piperidine-based renin inhibitors. Bioorg Med Chem 2005; 13: 59-68
PubMedGoogle Scholar
Speedel Experimenta AG. WO05061457; 2005
Google Scholar
Speedel Experimenta AG. WO06005741; 2006
Google Scholar
Speedel Experimenta AG. WO06103275; 2006
Google Scholar
Speedel Experimenta AG. WO06103273; 2006
Google Scholar
Speedel Experimenta AG. WO07082907; 2007
Google Scholar
Speedel Experimenta AG. WO06103277; 2006
Google Scholar
Successful outcome of Aliskiren, the first-in-class renin inhibitor, vs. Irbesartan, in a 650 patient hypertension study, recently completed by Novartis. Available from: http://www.speedelpharma.com/section/7/subsections/4?form_link=1094654092
Google Scholar
Werner-Lambert Co. WO04089915; 2004
Google Scholar
Holsworth DD, Powell NA, Downing DM, et al. Discovery of novel non-peptidic ketopiperazine-based renin inhibitors. Bioorg Med Chem 2005;13:2657-64
PubMedGoogle Scholar
Holsworth DD, Cai C, Cheng X-M, et al. Ketopiperazine-based renin inhibitors: Optimization of the “C” ring. Bioorg Med Chem Lett 2006;16:2500-4
PubMedGoogle Scholar
Powell NA, Clay EH, Holsworth DD, et al. Benzyl ether structure-activity relationships in a series of ketopiperazine-based renin inhibitors. Bioorg Med Chem Lett 2005;15:4713-6
PubMedGoogle Scholar
Powell NA, Clay EH, Holsworth DD, et al. Equipotent activity in both enantiomers of a series of ketopiperazine-based renin inhibitors. Bioorg Med Chem Lett 2005;15:2371-4
PubMedGoogle Scholar
Speedel Experimenta AG. WO05037803; 2005
Google Scholar
Novartis AG. WO06128659; 2006
Google Scholar
Actelion Pharm. Ltd. WO07034445; 2007
Google Scholar
Takeda Pharm. Co. WO07094513; 2007
Google Scholar
Takeda Pharm. Co. WO07117961; 2007
Google Scholar
Novartis AG. WO06117183; 2006
Google Scholar
Novartis AG. WO07006534; 2007
Google Scholar
Novartis AG. WO07077005; 2007
Google Scholar
Speedel Experimenta AG. WO07141318; 2007
Google Scholar
Novartis AG. WO06069788; 2006
Google Scholar
Novartis AG. WO06100036; 2006
Google Scholar
Novartis AG. WO07144129; 2007
Google Scholar
Novartis AG. WO07144128; 2007
Google Scholar
Actelion Pharm. Ltd. WO07034406; 2007
Google Scholar
Merck Frosst Canada Ltd. WO07009250; 2007
Google Scholar
Actelion Pharm. Ltd. WO07099509; 2007
Google Scholar
Vitae Pharm., Inc. WO06042150; 2006
Google Scholar
Vitae Pharm., Inc. WO07117560; 2007
Google Scholar
Vitae Pharm., Inc. WO07117559; 2007
Google Scholar
Vitae Pharm., Inc. WO07117557; 2007
Google Scholar
Vitae Pharm. Inc. WO07070201; 2007
Google Scholar
Vitae pharm., Inc. WO08036247; 2008
Google Scholar
Vitae Pharm., Inc. WO08036216; 2008
Google Scholar
Boger J, Lohr NS, Ulm EH, et al. Novel renin inhibitors containing the amino acid statine. Nature 1983;303:81-4
PubMed Web of Science ®Google Scholar
Cole DC, Manas ES, Stock JR, et al. Acylguanidines as small-molecule β-secretase inhibitors. J Med Chem. 2006;49:6158-61
PubMed Web of Science ®Google Scholar
Murray CW, Callaghan O, Chessari G, et al. Application of fragment screening by X-ray crystallography to β-sceretase. J Med Chem 2007;50:1116-23
PubMed Web of Science ®Google Scholar
Congreve M, Aharony D, Albert J, et al. Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of β-secretase. J Med Chem. 2007;50:1124-32
PubMed Web of Science ®Google Scholar
Cole DC, Stock JR, Chopra R, et al. Acylguanidine inhibitors of β-secretase: optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets. Bioorg Med Chem Lett. 2008;18:1063-6
PubMed Web of Science ®Google Scholar
Schering Corp.; Pharmacopeia Drug Discovery, Inc. WO05058311; 2005
Google Scholar
Schering Corp.; Pharmacopeia Drug Discovery, Inc. WO06065277; 2006
Google Scholar
Schering Corp.; Pharmacopeia Drug Discovery, Inc. WO06138265; 2006
Google Scholar
Schering Corp. WO06138266; 2006
Google Scholar
Sanofi-Aventis. WO07144769; 2007
Google Scholar
Holsworth DD, Jalaie M, Belliotti T, et al. Discovery of 6-ethyl-2,4-diaminopyrimidine-based small molecule renin inhibitors. Bioorg Med Chem Lett 2007;17:3575-80
PubMedGoogle Scholar
Powell NA, Ciske FL, Cai C, et al. Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem 2007;15:5912-49
PubMedGoogle Scholar
Sarver RW, Peevers J, Cody WL, et al. Binding thermodynamics of substituted diaminopyrimidine renin inhibitors. Anal Biochem 2007;360:30-40
PubMed Web of Science ®Google Scholar
Merrill J. Pfizer Shrugs at Novartis' Tekturna Launch. The Pink Sheet Daily 2007; March 14 Issue
Google Scholar
Novartis AG. WO05051895; 2005
Google Scholar
Speedel Experimenta AG. WO06095020; 2006
Google Scholar
Speedel Experimenta AG. WO07031557; 2007
Google Scholar
Speedel Experimenta AG. WO05070877; 2005
Google Scholar
Speedel Experimenta AG. WO07031558; 2007
Google Scholar
Speedel Experimenta AG. WO07085651; 2007
Google Scholar
Vitae Pharm., Inc. WO06003489; 2006
Google Scholar
Vitae Pharm., Inc. WO07120523; 2007
Google Scholar
Daiichi Sankyo Company, Ltd. WO07148775; 2007
Google Scholar
Daiichi Sankyo Company, Ltd. WO07148774; 2007
Google Scholar
Vitae Pharm., Inc. WO07123718; 2007
Google Scholar
Poindexter GS, Bruce MA, Guy Breitenbucher, et al. Dihydropyridine neuropeptide Y Y1 receptor antagonists 2: bioisosteric urea replacements. Bioorg Med Chem 2004;12:507-21
PubMed Web of Science ®Google Scholar
Vaidyanathan S, Jin Y, Schiller H, et al. Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzyme in vitro. Basic Res Pharmacol Toxicol 2005;97(Suppl 1):239
Google Scholar
Novartis AG. WO06013094; 2006
Google Scholar
Novartis AG. WO05051895; 2005
Google Scholar
Novartis AG. WO05054177; 2005
Google Scholar
Nicox S A. WO07045551; 2007
Google Scholar
Nicox S A. WO07104652; 2007
Google Scholar
Speedel Experimenta AG. WO08017685; 2008
Google Scholar
Gleeson MP: Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem 2008;51:817-34
PubMed Web of Science ®Google Scholar
Next generation of renin inhibitors – Dr. JC Jensen – Speedel R&D Day. 29 November 2006. Available from: http://www.speedel.com/assets/9%20Chris%20Jensen%20Next%20Generation%20Renin%20Inhibitors%20R&D%20Day%2029%20Nov%202006.pdf
Google Scholar
Speedel announces start of SPP635 Phase IIA trial in diabetic patients. Available from: http://www.speedel.com/speedelnew/section/7/subsections/0?pr_url=http://cws.huginonline.com/S/135077/PR/200712/1174499.xml
Google Scholar
Speedel Company Fact Sheet. Available from: http://www.speedel.com/assets/speedel_corp_factsheetnew.pdf
Google Scholar
Actelion/Merck & Co., Inc. Renin alliance achieves fourth milestone – Dosing in Phase II initiated – Actelion receives USD 10 million. Available from: http://www.actelion.com/uninet/www/www_main_p.nsf/Content/me+05+Dec+2007
Google Scholar
Vitae Pharmaceuticals: Product Focus. Available from: http://www.vitaepharma.com/pipeline/index.php#Hyper
Google Scholar
Press release issued Monday 20 June 2005-GlaxoSmithKline and Vitae Pharmaceuticals Establish Strategic Alliance to Develop and Commercialise Novel Hypertension Treatment. Available from: http://www.vitaepharma.com/news/NewsRelease2005Jun20.pdf
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Recent advances in the discovery of non-peptidic direct renin inhibitors as antihypertensives: new patent applications in years 2000 – 2008

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Recent advances in the discovery of non-peptidic direct renin inhibitors as antihypertensives: new patent applications in years 2000 – 2008

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date